Yes, lymphoma is a blood cancer. It develops in lymphocytes, a type of white blood cell that normally helps your body fight infections. Unlike leukemia, which primarily circulates in the blood and bone marrow, lymphoma cells tend to cluster and form solid masses in lymphatic tissues, particularly lymph nodes. This distinction sometimes causes confusion, since lymphoma produces visible tumors that can feel more like a “solid” cancer, but it originates in blood cells and is classified as a hematologic (blood) malignancy.
Why Lymphoma Counts as a Blood Cancer
Your lymphatic system is deeply intertwined with your blood. Lymphocytes are produced in the bone marrow, mature in various lymphatic organs, and circulate through both the bloodstream and a network of lymph vessels. When a lymphocyte becomes cancerous and begins dividing uncontrollably, the resulting disease is categorized alongside leukemia and multiple myeloma as one of the three major blood cancers.
The key difference between them comes down to where the cancer cells accumulate. In leukemia, cancerous cells are found circulating in the blood and bone marrow. In multiple myeloma, the cancer involves a specific subset of white blood cells that cluster in the bone marrow. In lymphoma, the abnormal cells aggregate into tumors within lymphatic tissues, most often in the lymph nodes, spleen, or thymus. All three start in blood cells, but they behave differently once they take hold.
Hodgkin vs. Non-Hodgkin Lymphoma
Lymphoma splits into two broad categories: Hodgkin lymphoma and non-Hodgkin lymphoma. The distinction comes down to what the cancer cells look like under a microscope. If a pathologist identifies a specific abnormal cell called a Reed-Sternberg cell, the lymphoma is classified as Hodgkin. If that cell isn’t present, it’s non-Hodgkin.
Hodgkin lymphoma almost always arises from B lymphocytes, one of the two main types of immune cells. Non-Hodgkin lymphoma is more varied. It can develop from B lymphocytes, T lymphocytes, or natural killer cells, which means it encompasses dozens of distinct subtypes that range from very slow-growing (indolent) to highly aggressive. Non-Hodgkin lymphoma is far more common. An estimated 79,320 new cases will be diagnosed in the U.S. in 2026 alone.
Symptoms to Recognize
The most noticeable early sign of lymphoma is typically a painless, swollen lymph node, often in the neck, armpit, or groin. But lymphoma also produces a set of systemic symptoms that doctors call “B symptoms,” which carry specific diagnostic meaning:
- Unexplained fever above 100.4°F (38°C)
- Drenching night sweats severe enough to require changing bedclothes
- Unexplained weight loss of more than 10% of your body weight within six months
The presence or absence of B symptoms affects how the cancer is staged and can influence treatment decisions. Other symptoms like fatigue, itching, or alcohol-induced pain at the site of a tumor can occur but aren’t formally included in the B symptom classification. Because these symptoms overlap with many common illnesses, lymphoma is sometimes caught late, particularly the slower-growing subtypes.
How Lymphoma Is Diagnosed
A lymphoma diagnosis almost always requires a biopsy of a suspicious lymph node. Surgical excision, where the entire node is removed, is the gold standard. It allows pathologists to examine the full architecture of the tissue and provides enough material for specialized testing. In a large French study, surgical excision produced a definitive diagnosis in 98.1% of cases, compared to 92.3% for needle-based core biopsies. Core biopsies also had higher rates of disagreement between local and expert pathologists.
This matters because accurately classifying the exact subtype of lymphoma is critical for choosing the right treatment. Expert pathology review is recommended regardless of biopsy type, but especially when only a core biopsy sample is available.
Staging: How Far It Has Spread
Lymphoma is staged using a four-tier system that tracks how many lymph node regions are involved and whether the cancer has spread beyond the lymphatic system:
- Stage I: Cancer is in a single lymph node region.
- Stage II: Cancer involves two or more lymph node regions, but only on one side of the diaphragm (either above or below it).
- Stage III: Cancer is found in lymph node regions on both sides of the diaphragm.
- Stage IV: Cancer has spread beyond the lymphatic system into organs like the bone marrow, liver, or lungs.
Each stage also receives a letter. “A” means no B symptoms are present. “B” means the patient has at least one of the systemic symptoms described above. An “E” designation indicates the cancer has extended into tissue directly adjacent to a lymph node, while “S” indicates involvement of the spleen.
Survival Rates for Non-Hodgkin Lymphoma
The overall five-year survival rate for non-Hodgkin lymphoma is 74.3%, based on recent SEER data from 2016 to 2022. Stage at diagnosis makes a significant difference. When the cancer is confined to a single region (Stage I), the five-year survival rate is 87.6%. For Stage II, it’s 79.7%. Stage III drops to 74.0%, and Stage IV, where the cancer has spread widely, sits at 63.6%.
These are averages across all non-Hodgkin subtypes, which is important context. Some slow-growing forms, like follicular lymphoma, often have survival rates well above these numbers. Aggressive subtypes like diffuse large B-cell lymphoma (DLBCL) have lower survival rates if they don’t respond to initial treatment, but many patients with aggressive lymphoma are cured outright. Hodgkin lymphoma generally has even better outcomes, with five-year survival rates above 85%.
How Lymphoma Is Treated
Treatment depends heavily on the specific subtype, stage, and how aggressive the cancer is. For the most common aggressive form, DLBCL, the backbone of treatment for over 20 years has been a combination of chemotherapy drugs paired with rituximab, a lab-made antibody that targets a protein on the surface of B cells. This combination cures a substantial number of patients.
More recently, newer combinations have shown improvement. One approach swaps out one of the traditional chemotherapy drugs for an antibody-drug conjugate, a therapy that delivers chemotherapy directly to cancer cells. This regimen showed better progression-free survival in clinical trials and is now an option for higher-risk DLBCL patients.
For patients whose lymphoma comes back or doesn’t respond to initial treatment, the options have expanded considerably. A class of drugs called bispecific antibodies work by physically linking a patient’s immune T cells to cancer cells, forcing the immune system to attack the tumor. Two of these agents are approved for DLBCL that has relapsed after two or more prior treatments. CAR-T cell therapy, where a patient’s own immune cells are genetically modified in a lab to recognize and kill lymphoma cells, is another option for relapsed disease and has produced durable remissions in a subset of patients.
Slow-growing lymphomas are handled differently. Some don’t need treatment immediately and are monitored with a “watch and wait” approach until they cause symptoms or show signs of progression. When treatment is needed, it often involves the same antibody-based therapies, sometimes combined with gentler chemotherapy regimens.